359 related articles for article (PubMed ID: 24117205)
1. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.
Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P
Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans.
Landriscina M; Pannone G; Piscazzi A; Toti P; Fabiano A; Tortorella S; Occhini R; Ambrosi A; Bufo P; Cignarelli M
Thyroid; 2011 Nov; 21(11):1227-34. PubMed ID: 22007939
[TBL] [Abstract][Full Text] [Related]
3. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
[TBL] [Abstract][Full Text] [Related]
5. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
6. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
8. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation.
Amacher AM; Goyal B; Lewis JS; El-Mofty SK; Chernock RD
Am J Surg Pathol; 2015 Feb; 39(2):260-5. PubMed ID: 25321328
[TBL] [Abstract][Full Text] [Related]
10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma.
Chen Z; Liu N; Zhu G; Dralle H; Hoang-Vu C
Int J Mol Med; 2012 Sep; 30(3):465-72. PubMed ID: 22751750
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.
Montero-Conde C; Martín-Campos JM; Lerma E; Gimenez G; Martínez-Guitarte JL; Combalía N; Montaner D; Matías-Guiu X; Dopazo J; de Leiva A; Robledo M; Mauricio D
Oncogene; 2008 Mar; 27(11):1554-61. PubMed ID: 17873908
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma.
Ito Y; Yoshida H; Uruno T; Nakano K; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Matsuura N; Kakudo K; Kuma K; Miyauchi A
Oncol Rep; 2003; 10(5):1337-40. PubMed ID: 12883703
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
15. Raf-1 kinase inhibitory protein expression in thyroid carcinomas.
Kim HS; Kim GY; Lim SJ; Kim YW
Endocr Pathol; 2010 Dec; 21(4):253-7. PubMed ID: 20734161
[TBL] [Abstract][Full Text] [Related]
16. Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors.
Xu J; Filetti S; Hershman JM
Thyroid; 2008 May; 18(5):533-9. PubMed ID: 18399756
[TBL] [Abstract][Full Text] [Related]
17. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
18. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.
Buehler D; Hardin H; Shan W; Montemayor-Garcia C; Rush PS; Asioli S; Chen H; Lloyd RV
Mod Pathol; 2013 Jan; 26(1):54-61. PubMed ID: 22899291
[TBL] [Abstract][Full Text] [Related]
19. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma.
Miettinen M; Franssila KO
Hum Pathol; 2000 Sep; 31(9):1139-45. PubMed ID: 11014583
[TBL] [Abstract][Full Text] [Related]
20. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
